Media coverage about Cellular Biomedicine Group (NASDAQ:CBMG) has trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellular Biomedicine Group earned a news impact score of 0.06 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.7113786544374 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s scoring:
- Cellular Biomedicine Group Inc (CBMG) Insider Yihong Yao Acquires 4,167 Shares (americanbankingnews.com)
- Cellular Biomedicine Group Inc (CBMG) SVP Andrew K. Chan Buys 8,333 Shares (americanbankingnews.com)
- Insider Buying: Cellular Biomedicine Group Inc (CBMG) CEO Acquires 29,167 Shares of Stock (americanbankingnews.com)
- Cellular Biomedicine Group Announces Closing of $14.5 Million Private Placement Offering (finance.yahoo.com)
- ETFs with exposure to Cellular Biomedicine Group, Inc. : December 28, 2017 (finance.yahoo.com)
Shares of Cellular Biomedicine Group (NASDAQ CBMG) traded up $1.25 during trading hours on Wednesday, hitting $12.50. 120,300 shares of the stock were exchanged, compared to its average volume of 76,700. Cellular Biomedicine Group has a 1-year low of $5.05 and a 1-year high of $13.80. The stock has a market capitalization of $200.98, a PE ratio of -7.23 and a beta of 2.82.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/01/03/cellular-biomedicine-group-cbmg-getting-somewhat-positive-press-coverage-study-finds.html.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.